Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Dana–Farber Cancer Institute (13)
2023
-
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106
-
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Journal of Clinical Medicine, Vol. 12, Núm. 1
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222
-
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
JAMA Oncology, Vol. 7, Núm. 12, pp. 1772-1781
2020
-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Lung Cancer, Vol. 150, pp. 90-96
-
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654
2018
-
Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy
Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3134-3143
2016
-
Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
Annals of Oncology, Vol. 27, pp. vi68
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
2014
-
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
Annals of Oncology, Vol. 25, Núm. 8, pp. 1656-1663
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541